Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...

Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was ...

Detailed results were released from the TROPION-Lung01 Phase III trial, which showed a clinically meaningful trend toward ...

AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) datopotamab deruxtecan (Dato-DXd) did not significantly improve overall ...

--(BUSINESS WIRE)--Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato ...

The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis. Overall survival results numerically favored datopotamab deruxtecan compared to docetaxel ...